Consultation responses

We respond to public consultations relating to prostate cancer care using our policy positions. We aim to inform and influence policy development to improve prostate cancer services and care.

Strengthening the NHS Constitution

Read our response to the Department of Health's consultation on the NHS Constitution.

NHS Standard Contract response: Urological cancers

Read our response to the NHS Standard Contract: Urological cancers for the NHS Commissioning Board.

CCG Indicator Consultation

Read our response to NICE's consultation on CCG Indicators.

Brachytherapy

Read our response to the consultation on NHS Commissioning Board Consultation on Brachytherapy services.

+

Older consultation responses

SMC consultation on new prostate cancer drugs, Sep 2011/Jan 2012

We responded to the Scottish Medicines Consortium's consultations on new prostate cancer drugs.

Read our response to the consultation on cabazitaxel.

Read our response to the consultation on abiraterone.

Detect cancer early initiative, Aug 2011

We responded to the Scottish Government's consultation on its Detect cancer early initiative. Read our response.

NICE consultations on new prostate cancer drugs, Aug/Sep 2011

We responded to NICE consultations on the reviews of two new prostate cancer drugs. We will continue to work with NICE while they develop recommendations on their use in England and Wales.

Read our response on the use of abiraterone after chemotherapy.

Read our response on the use of abiraterone before chemotherapy.

Read our response on denosumab.

NICE review of clinical guideline on prostate cancer, June 2011

Read about NICE's review of the prostate cancer clinical guideline.

Read our response to the review.

Value Based Pricing, March 2011

We responded to the Department of Health's consultation on proposals to establish a value-based system of pricing medicines. The system aims to change the way in which NHS patients access branded medicines. Read our full response.

Cancer Drugs Fund, Jan 2011

We responded to the Department of Health's consultation on proposals to establish a Cancer Drugs Fund from April 2011. The Fund is intended to improve access to cancer drugs prior to the anticipated reform of the current arrangements for branded drug pricing. Read our full response.

Prostate Cancer Screening, Sep 2010

We responded to a consultation on prostate cancer screening held by the UK National Screening Committee. Read the full response.

Review of the Cancer Reform Strategy, Sep 2010

We responded to the Government's consultation on the review of the 2007 Cancer Reform Strategy. This review was designed to update the Government's cancer strategy and ensure it is in line with the "Equity and Excellence: Liberating the NHS" White Paper. Read the full response.

We also fed into the Prostate Cancer Advisory Group's response to the review of the Cancer Reform Strategy. Read the full response.